Evidence map›Paper›PMID 37045879›Full record

ArticleScientific reports2023

Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.

Pyae Linn Aung, Myat Thu Soe, Than Naing Soe, Thit Lwin Oo, Kyawt Mon Win, Liwang Cui, Myat Phone Kyaw, Jetsumon Sattabongkot, Kamolnetr Okanurak, Daniel M Parker

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Pyae Linn AungMyanmar Health Network Organization, Yangon, Myanmar.
Myat Thu SoeMyanmar Health Network Organization, Yangon, Myanmar.
Than Naing SoeDepartment of Public Health, Ministry of Health, NayPyiTaw, Myanmar.
Thit Lwin OoMyanmar Health Network Organization, Yangon, Myanmar.
Kyawt Mon WinDepartment of Public Health, Ministry of Health, NayPyiTaw, Myanmar.
Liwang CuiDivision of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 3720 Spectrum Boulevard, Suite 304, Tampa, FL, 33612, USA.
Myat Phone KyawMyanmar Health Network Organization, Yangon, Myanmar.
Jetsumon SattabongkotMahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Kamolnetr OkanurakDepartment of Social and Environmental Health, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. kamolnetr.oka@mahidol.ac.th.
Daniel M ParkerDepartment of Population Health and Disease Prevention, Department of Epidemiology, University of California, Irvine, USA. dparker1@hs.uci.edu.
Myanmar Oxford Clinical Research Unit · MMMinistry of Health and Sports · MMMahidol Oxford Tropical Medicine Research Unit · THMahidol University · THUniversity of California, Irvine · USUniversity of South Florida · US

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672
6 · The paper itself

Abstract

Targeted mass primaquine treatment (TPT) might be an effective intervention to facilitate elimination of vivax malaria in Myanmar by 2030. In this study, we explored the factors hindering coverage of a TPT campaign conducted in a malarious township of northern Myanmar. From August 2019 to July 2020, a cross-sectional exploratory design including quantitative and qualitative data was conducted in five villages with high P. vivax prevalence following a TPT campaign. Among a targeted population of 2322; 1973 (85.0%) participated in the baseline mass blood survey (MBS) and only 52.0% of the total targeted population (1208, 91.9% of total eligible population) completed the TPT. G6PD deficiency was found among 13.5% of total MBS participants and those were excluded from TPT. Of 1315 eligible samples, farmers and gold miners, males, and those aged 15 to 45 years had higher percentages of non-participation in TPT. Qualitative findings showed that most of the non-participation groups were outside the villages during TPT because of time-sensitive agricultural and other occupational or education-related purposes. In addition to mitigating of some inclusion criteria (i.e. including young children or offering weekly PQ treatment to G6PD deficient individuals), strengthening community awareness and increasing engagement should be pursued to increase community participation.

Indexed as

AntimalarialsGlucosephosphate Dehydrogenase DeficiencyMalaria, VivaxChildChild, PreschoolCross-Sectional StudiesHumansMaleMyanmarPrimaquineAntimalarialsPrimaquine

Identifiers

PMID37045879
PMCPMC10091336
OpenAlexW4365142718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.